OB/GYN Clinical Alert
RSSArticles
-
Genetic Testing: Who Should Be Tested and What Should They Be Tested For?
Genetic testing has changed rapidly over the past three years, so to prevent cancer, it is critical that obstetricians-gynecologists take a complete family history, identify women at risk, and make appropriate referrals for genetic counseling with potential testing to prevent cancer.
-
Is an Even Safer Combined Oral Contraceptive Pill Available?
ABSTRACT & COMMENTARY: New study has many advantages, including ascertainment of important confounding variables.
-
HPV Vaccines: Why Are We Failing to Vaccinate so Many of Our Adolescents?
Given that this cancer is such a world health problem and the cost of screening is large and unreliable, HPV vaccines should substantially reduce the incidence and cost of both screening for and treating hrHPV-related diseases.
-
What Is the Best Way to Perform a Paracervical Block?
ABSTRACT & COMMENTARY: A randomized, controlled trial of first-trimester suction D&C procedures.
-
Factor V Leiden Mutation and Combined Hormonal Contraception? Is Thrombosis Risk Acceptable?
A meta-analysis of cohort studies supports that women with mild thrombophilias like heterozygote Factor V Leiden mutation can use combined hormonal contraception if other reliable methods are not acceptable.
-
Preterm Premature Rupture of Membranes: When to Deliver?
A recent large multicenter, randomized clinical trial has shown that delivering patients with premature preterm rupture of membranes at 34 weeks, rather than pursuing a watchful waiting approach until 37 weeks, does not afford greater protection against neonatal sepsis.
-
Endocrine-disrupting Chemicals and Female Reproductive Disorders
The endocrine-disrupting chemicals diphenyl-dichloroethene and phthalates appear to contribute substantially to the incidence of the most common reproductive disorders in women, endometriosis and fibroids, and lead to total costs of 1.5 billion euros in the European Union.
-
Still Highly Effective: LNG IUS 52 mg at 7 Years
Data from a large randomized study conducted by the World Health Organization demonstrate that pregnancy rates do not increase after year five, and support the continued use of the levonorgestrel intrauterine system 52 mg for contraception through seven years.
-
Infection Risk with Same-day Testing and IUD Insertion
In this prospective trial of same-day chlamydia/gonorrhea testing with intrauterine device insertion among 1,714 women, the risk of subsequent pelvic infection was extremely low (0.2%) over two years of follow-up.
-
Prolonged Second Stage of Labor
A recent randomized clinical trial has shown that using a more liberal threshold for second stage labors in nulliparous patients with and without epidural can result in a major decrease in the need for cesarean sections.